New drug shows promise in controlling transplant complications

NCT ID NCT03763318

Completed Disease control Sponsor: Biocon Limited Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new drug called EQ001 in 30 people who developed acute graft-versus-host disease (aGVHD) after a stem cell transplant. aGVHD is a serious condition where donor immune cells attack the patient's body. The goal was to see if EQ001 is safe and can help control this immune reaction. Participants received the drug and were monitored for side effects and treatment response.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute graft versus host disease graft versus host disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE GRAFT VERSUS HOST DISEASE AGVHD GVHD GVHD, ACUTE

Contacts and locations

Locations

City of Hope Comprehensive Cancer Center

Duarte, California, 91010, United States
Dana-Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Emory University Hospital

Atlanta, Georgia, 30322, United States
Fred Hutchinson Cancer Research Center

Seattle, Washington, 98109-4433, United States
H. Lee Moffitt Cancer Center & Research Institute

Tampa, Florida, 33612, United States
Intermountain Healthcare

Salt Lake City, Utah, 84103, United States
Oregon Health & Science University

Portland, Oregon, 97239, United States
Roswell Park Cancer Institute

Buffalo, New York, 14263, United States
TriStar Centennial Medical Center (SCRI)

Nashville, Tennessee, 53719, United States
University of Florida Health Shands Hospital

Gainesville, Florida, 32610, United States
University of Miami - Miller School of Medicine

Miami, Florida, 33136, United States
University of Michigan - C.S. Mott Children's Hospital

Ann Arbor, Michigan, 48109, United States
University of North Carolina Lineberger Comprehensive Cancer Center

Chapel Hill, North Carolina, 27599, United States
University of Pennsylvania, Abramson Cancer Center

Philadelphia, Pennsylvania, 19104, United States
University of Pittsburgh Cancer Institute

Pittsburgh, Pennsylvania, 15232, United States
Washington University and Barnes Jewish Heart & Vascular Center

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.